We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

44 hedge funds and large institutions have $18.9M invested in CASI Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.33% less ownership

Funds ownership: 2% → 1.67% (-0.33%)

14% less funds holding

Funds holding: 51 → 44 (-7)

16% less capital invested

Capital invested by funds: $22.4M → $18.9M (-$3.48M)

60% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 10

64% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 14

Holders
44
Holders Change
-7
Holders Change %
-13.73%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
14
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WSC
Wellington Shields & Co
New York
+$245K
2
Citadel Advisors
Citadel Advisors
Florida
+$106K
3
IC
Ikarian Capital
Texas
+$76.3K
4
Citigroup
Citigroup
New York
+$57.4K
5
VF
Virtu Financial
New York
+$25.1K

Top Sellers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$1.34M
2
Renaissance Technologies
Renaissance Technologies
New York
-$1.02M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$620K
4
Marshall Wace
Marshall Wace
United Kingdom
-$241K
5
AFM
Anson Funds Management
Texas
-$214K

CASI Hedge Fund Activity: Q1 2022 in Review

44 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q1 2022, worth a combined $18.9M — down 16% from $22.4M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of CASI and 4 opened new positions — a net loss of 6 holders — while 14 trimmed existing stakes and 5 added.

The largest buyer was Wellington Shields & Co, adding an estimated $245K. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $1.34M sold.

  • 44 institutional investors held CASI Pharmaceuticals (CASI) as of Q1 2022, down from 51 in Q4 2021.
  • Funds reported $18.9M of CASI Pharmaceuticals stock for Q1 2022, down 16% quarter-over-quarter.
  • 4 funds opened new CASI Pharmaceuticals positions in Q1 2022 and 10 closed out, a net change of -6 holders.
  • The largest CASI Pharmaceuticals buyer in Q1 2022 was Wellington Shields & Co, an estimated $245K added.
  • The largest CASI Pharmaceuticals seller in Q1 2022 was Jacobs Levy Equity Management, an estimated $1.34M sold.

Based on aggregated 13F filings for Q1 2022.